Single-dose capivasertib testing in people with moderate liver impairment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-dose, open-label, non-randomized, parallel-group pharmacokinetic and safety study comparing participants with moderate hepatic impairment (Child-Pugh class B) to participants with normal hepatic function. Eligible participants will be resident at the site from the day before dosing through Day 4, receive one oral dose of capivasertib on Day 1, and return for a follow-up visit on Days 9–11. The study will collect blood samples for pharmacokinetic analysis and monitor safety and tolerability through clinical assessments and laboratory tests. The goal is to characterize how liver impairment affects drug exposure and short-term safety signals to inform dosing recommendations.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* Body weight of at least 50 kg and Body Mass Index (BMI) of between ≥ 18 up to ≤ 40 kg/m2.
* Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* Participants must have suitable veins for cannulation or repeated venipuncture.
* Non-smoker, defined as a participant who has not smoked previously or who has discontinued smoking or the use of other nicotine/nicotine-containing products at least 3 months before the Screening Visit.
* Supporting documents confirming the participant's hepatic impairment must be available (a liver biopsy is preferable but not mandatory); participants must be classified by the Investigator as Child Pugh class B.
* Participants must meet National Cancer Institute - Organ Dysfunction Working Group (NCI-ODWG) classification of total bilirubin 1.5 to 3\*upper limit of normal (ULN) and any Aspartate aminotransferase/transaminase (AST) for moderate hepatic impairment.
* Stable hepatic impairment
* For participants with normal hepatic function, Bilirubin \< 1.5 × ULN, alanine aminotransferase (ALT), AST, albumin, alkaline phosphatase (ALP), gamma glutamyl transferase (GGT) \< 1.2 × ULN. Creatinine \< ULN. White blood cell count \> lower limit of normal (LLN).

Key Exclusion Criteria:

* Any evidence of diseases (such as severe or uncontrolled systemic diseases, including uncontrolled hypertension, significant aneurysm, renal transplant and active bleeding diseases) which makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.
* Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of capivasertib.
* History of primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include adequately resected non-melanoma skin cancer and curatively treated in situ disease.
* Active tuberculosis infection.
* Known Human Immunodeficiency Virus (HIV) infection, active hepatitis B or C infection, positive hepatitis C antibody, and/or positive hepatitis B virus surface antigen.
* Clinically significant abnormalities of glucose metabolism as defined by HemoglobinA1c (HbA1c) ≥ 8.0% (63.9 mmol/mol) at screening.
* Moderate or severe renal dysfunction according to age-related creatinine clearance estimated using CKD-EPI formula (i.e., creatinine clearance less than 60 mL/min).
* Fluctuating or rapidly deteriorating hepatic function.
* Presence of a hepatocellular carcinoma or acute liver disease caused by an infection or drug toxicity.
* Severe portal hypertension or surgical porto-systemic shunts.
* Biliary obstruction or other causes of hepatic impairment not related to parenchymal disorder and/or disease of the liver.
* Clinically relevant hepatic encephalopathy (Grade 3 or more).
* Severe ascites.
* Esophageal variceal bleeding (unless banded) within the past 2 months.
* Post-liver transplantation.

Where it's running

• Research Site
  Rialto, California, United States Recruiting
• Research Site
  San Antonio, Texas, United States Recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Single-dose zanzalintinib testing in people with moderate liver impairment

  This will test how one dose of zanzalintinib behaves in the blood of people with moderate liver impairment compared with healthy people.

  Recruiting at 2 sites Phase 1 Exelixis · Orlando, Florida and 1 other locations · NCT06962332

• Understanding the disease burden of hypophosphatasia in Chinese patients

  This study tests how hypophosphatasia affects people in China by collecting real-world data on symptoms, quality of life, and costs.

  Recruiting AstraZeneca · Beijing and 21 other locations · NCT07905287

• Real-world use of selumetinib for adult NF1 with inoperable plexiform neurofibromas

  This registry-following study tests how well and safely selumetinib works in adults with NF1 who have symptomatic, inoperable PN.

  Recruiting AstraZeneca · Beijing and 25 other locations · NCT07888517

• Durvalumab with FLOT before and after surgery for resectable gastric/GEJ cancer in Chinese patients

  This trial tests whether adding durvalumab to FLOT chemotherapy before and after surgery helps Chinese patients with resectable gastric or gastroesophageal junction cancer.

  Recruiting at 11 sites Phase 3 AstraZeneca · Beijing and 40 other locations · NCT07877818

• Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer

  This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.

  Recruiting at 4 sites Phase 3 AstraZeneca · Tamarac, Florida and 219 other locations · NCT07851025

• AZD0543 safety and PK in healthy adults

  This study tests whether AZD0543 is safe and how it behaves in the body compared with a placebo in healthy adults age 18–55.

  Recruiting at 2 sites Phase 1 AstraZeneca · Los Alamitos, California and 1 other locations · NCT07824622

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.